CN1087628C - Developer for supersonic diagnosis of oviduct and its use - Google Patents
Developer for supersonic diagnosis of oviduct and its use Download PDFInfo
- Publication number
- CN1087628C CN1087628C CN98112412A CN98112412A CN1087628C CN 1087628 C CN1087628 C CN 1087628C CN 98112412 A CN98112412 A CN 98112412A CN 98112412 A CN98112412 A CN 98112412A CN 1087628 C CN1087628 C CN 1087628C
- Authority
- CN
- China
- Prior art keywords
- developer
- oviduct
- diagnosis
- supersonic
- stabilizing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a developer for the supersonic diagnosis of oviducts and a purpose thereof, and relates to a preparation product for supersonic diagnosis. The present invention provides a liquid developer composed of a water soluble carrier with oxygen, which is proportionally prepared from a basal body, a stabilizing agent and a bubble suppressing agent. After the developer is injected into the uterine cavity, micro oxygen bubbles are generated under the action of a body liquid enzyme of the uterine cavity. Consequently, an acoustic image with a strong relative property is formed. The developer has the advantages of simple and convenient supersonic development method, rapidness, clear images, high resolution, no toxic or side effect, no stimulation, and safe use; the developer can also be used as medicine for dredging clogged oviducts and is worth popularizing and applying.
Description
Fallopian tube imaging agent for ultrasonic diagnosis and uses thereof relates to the preparation that is used for ultrasonic diagnosis.
Colour developing and X-ray lipiodol angiography in the phenol red urine are mainly adopted in fallopian tube inspection before, and the former interference factor is many, and the result is inaccurate, and the latter is the iodized oil side effect, and complication reaches X-ray more human body is damaged, and therefore use clinically to be subjected to certain limitation.Ultrasonic is a kind of undamaged inspection method, developed recently is very fast, welcome by patient, but the tiny fallopian tube state with structures surrounding shortage comparative there is not distinguishing ability owing to ultrasonic, do not reflect actual change, therefore, a kind of developer that can improve the fallopian tube diagnosis usefulness of ultrasound contrast of clinical needs.
The present invention with regard to be to provide a kind of comparative strong, have no side effect, developer that supersonic diagnosis of oviduct easy and simple to handle is used.
The technical scheme that realizes the foregoing invention purpose is:
With peroxidating carbon diamides is matrix, with any used as stabilizers in disodiumedetate, benzoic acid, P-hydroxybenzoic acid first, ethyl ester, the 3-hydroxyl carboxyl 1,3-propanedicarboxylic acid, with dihydroxypropane or trihydroxy propane is foam inhibitor and solvent, matrix and stabilizing agent successively are dissolved in the solvent with the weight ratio of 50-150: 0.1-15, adjust PH at 3-4.5, make 1000 parts developer, after filtration, the fill, standby under aseptic condition; The content disodiumedetate of described stabilizing agent is 0.05%, benzoic acid 0.1%, P-hydroxybenzoic acid first, ethyl ester 0.01%, 3-hydroxyl carboxyl 1,3-propanedicarboxylic acid 0.1～0.3%, stabilizing agent is good with 3 hydroxyl carboxyl 1,3-propanedicarboxylic acids, foam inhibitor is good with trihydroxy propane, and developer of the present invention can be used as the oviducal medicine that mediation is blocked.
Be described in further detail the present invention below.
The developer that supersonic diagnosis of oviduct adopts is a kind of colourless transparent liquid preparation, be a kind of carrier of oxygen that contains, the mechanism of action of its video picture is, imaging liquid enters each section of fallopian tube injecting into the uterus, under the effect of uterine cavity and fallopian tube body fluid enzyme, disintegrate rapidly, after the disintegration, the nascent oxygen and the molecular oxygen that produce form little oxygen bubbles, little oxygen bubbles aperture can enter fine each section of fallopian tube through the uterus smoothly at 40-90mm, produces intensive echo, be formed with the acoustic picture of comparability, thereby realize the ultrasonoscopy inspection.Dihydroxypropane in the developer, trihydroxy propane be solvent be again foam inhibitor, should be water solublity as foam inhibitor, can fully combine with body fluid, lubricity is good, is easy to by tiny fallopian tube; Relative density is more than 1.25.The foam inhibitor that the present invention adopts is good with trihydroxy propane.Foam inhibitor both can promote little oxygen bubbles to form, and can stop instantaneous the interosculating of minute bubbles to become big again, form anechoic big oxygen bubble, thereby it was lasting to keep image.
When adopting developer of the present invention to implement ultrasonic examination, press the hydrotubation maneuver, at the good water flowing head of cervix uteri interpolation, feed earlier 0.9% normal saline 5ml (in add atropine 0.5mg), slowly inject, get developer 3-5ml, normal saline 10-20m1 dilution with 0.9%, as seen mixing, developer are inverted leg-of-mutton strong cloud of echoes after injecting in the uterine cavity, its rear is " comet tail " and levies image, ultra micro oxygen bubble flows to two oviductus lateraliss rapidly, is full of until the full section of fallopian tube, and little oxygen bubble is overflowed from the umbrella end.
Developer of the present invention only is to be examined the echo that target position forms comparative, does not involve other organizer palaces of whole body, and each component of developer has no side effect and zest, and is safe in utilization.The stability of developer shows with catabolite mensuration and three indexs investigations of appearance character result through changes of contents that better under 16 ℃ of temperature conditions, preserved 1 year, content loss loss 10% in 2%, two year conforms to quality requirements.
Through clinical observation 34 examples, confirm to adopt this developer, video picture is quick, clear picture, the resolution height, easy and simple to handle, safe in utilization, all are tried the patient, and uterine cavity internal stimulus or other side effect take place in none.
This developer not only improves the contrast of fallopian tube ultrasonoscopy, and can be used as the medicine of dredging oviduct.Because developer has the bactericidal action of pressing down at nascent oxygen and the carbonic acid diamides that target position discharges to antibacterial, mycete, particularly the common Candida albicans accessory of genitals there is the very strong bactericidal action that presses down, it presses down bactericidal action intensity and high concentration nystatin (100M unit/ml) suitable, to 8 kinds of average inhibition zones of Candida albicans strain is 16.5mm (seeing attached list), therefore, help to remove, bacterial digestion infects inflammation and the macromole adhesion liquid that causes.Subordinate list:
Developer is to the Candida albicans bacteriostasis
| Candida albicans belongs to (bacterial strain number) | The test group matched group |
| Developer nystatin (stock solution) (the inhibition zone mm inhibition zone mm of 100M unit/ml) | |
| 1 2 3 4 5 6 7 8 | 19 19 16 16 17 17 17 17 16 17 16 16 19 17 16 17 |
| Total inhibition zone | 136 132 |
| Average inhibition zone | 17.0 16.5 |
| P＞0.05 | |
The test group developer is suitable with matched group nystatin 100M unit/antibacterial power of ml, and no significance is different poor.
High-density solvent can change local surface tension, increases the active ingredient diffusion, penetrates into the inflammation organization internal, decomposing macromolecular inflammation secreting mucus.This developer can change the surface tension of inflammation part, and penetration is strong, can be used as to eliminate genitals's inflammation, the medicine of dredging oviduct.Its using method generally should be after the fallopian tube ultrasonic examination be injected this developer in one month again, method and ultrasonoscopy are together, can improve the fallopian tube patency rate, with clinical video picture observe in 34 examples 12 examples be test group and iodized oil X-ray radiography group and two matched groups of conventional water flowing group relatively, the result is as follows:
The unobstructed fraction defective blocking rate of unobstructed good rate
Test group 50% (6/12) 50% (6/12) 0% (0/12)
Iodized oil X-ray radiography group 33.3% (4/12) 16.7% (2/12) 50/% (6/12)
Conventional water flowing art group 8.3% (1/12) 25% (3/12) 66.7% (8/12)
The present invention is according to fallopian tube ultrasonic development this purpose, the imaging liquid agent of adopting the oxygenated water solubleness carrier to form, little oxygen bubbles that developer produces under the effect of uterine cavity body fluid enzyme forms the acoustic picture of intensive echo and comparability at target position, thereby realize the fallopian tube ultrasonoscopy, use this developer ultrasonic contrast method easy, quick, clear picture, resolution height, have no side effect and zest, safe in utilization, but the oviducal medicine that double as mediation is simultaneously blocked is a kind of supersonic diagnosis of oviduct developer that promotional value is arranged.
Embodiment:
Peroxidating carbon diamides 80g, 3-hydroxyl carboxyl 1,3-propanedicarboxylic acid 2g is dissolved in the 918g trihydroxy propane successively, and is extremely clear and bright through aseptic filtration, and fill is standby.
Claims (5)
1, the developer used of a kind of supersonic diagnosis of oviduct, it is characterized in that with peroxidating carbon diamides be matrix, with disodiumedetate, benzoic acid, P-hydroxybenzoic acid first, ethyl ester, any is a stabilizing agent in the 3-hydroxyl carboxyl 1,3-propanedicarboxylic acid, with dihydroxypropane or trihydroxy propane is foam inhibitor and solvent, matrix and stabilizing agent are with 50～150: 0.1～15 weight ratio successively is dissolved in the solvent, adjusting pH value is 3～4.5, be mixed with 1000 parts developer, standby after filtering fill under the aseptic condition.
2, the developer of using by the described supersonic diagnosis of oviduct of claim 1 is characterized in that the content of stabilizing agent, and disodiumedetate is 0.05%, benzoic acid 0.1%, P-hydroxybenzoic acid first, ethyl ester 0.01%, 3-hydroxyl carboxyl 1,3-propanedicarboxylic acid 0.1～3%.
3, the developer of using by claim 1 or 2 described supersonic diagnosis of oviduct is characterized in that stabilizing agent is a 3-hydroxyl carboxyl 1,3-propanedicarboxylic acid.
4, the developer of using by right 1 described supersonic diagnosis of oviduct is characterized in that foam inhibitor is a trihydroxy propane.
5, the application of the described developer for supersonic diagnosis of oviduct of claim 1 in the oviducal medicine that preparation is blocked as mediation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98112412A CN1087628C (en) | 1998-03-27 | 1998-03-27 | Developer for supersonic diagnosis of oviduct and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98112412A CN1087628C (en) | 1998-03-27 | 1998-03-27 | Developer for supersonic diagnosis of oviduct and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1230438A CN1230438A (en) | 1999-10-06 |
| CN1087628C true CN1087628C (en) | 2002-07-17 |
Family
ID=5222265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98112412A Expired - Fee Related CN1087628C (en) | 1998-03-27 | 1998-03-27 | Developer for supersonic diagnosis of oviduct and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1087628C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001089584A2 (en) * | 2000-05-23 | 2001-11-29 | Amersham Health As | Contrast agents |
-
1998
- 1998-03-27 CN CN98112412A patent/CN1087628C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 云南医药1995;16(2):113-114 1995.1.1 邹美良 陈兰君 B超观察下双氧水子宫输卵管造影 * |
| 宁夏医学院学报1997;(3);60-61 1997.1.1 蔡中 梁诗颂 子宫输卵管造影的理想造影剂－泛影葡胺胶浆 * |
| 宁夏医学院学报1997;(3);60-61 1997.1.1 蔡中 梁诗颂 子宫输卵管造影的理想造影剂－泛影葡胺胶浆;云南医药1995;16(2):113-114 1995.1.1 邹美良 陈兰君 B超观察下双氧水子宫输卵管造影 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1230438A (en) | 1999-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gosling et al. | A comparative study of the human external sphincter and periurethral levator ani muscles | |
| Wikland et al. | Collection of human oocytes by the use of sonography | |
| US8343462B2 (en) | Formulations for use in medical and diagnostic procedures | |
| DE3313946A1 (en) | MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS | |
| Vick et al. | CT of the normal and abnormal parametria in cervical cancer | |
| Kremer et al. | Ultrasonic in vivo and in vitro studies on the nature of the ureteral jet phenomenon. | |
| Gilpin et al. | Smooth muscle in the wall of the developing human urinary bladder and urethra. | |
| US5093106A (en) | Method for contrasting malignant neoplasms using fluorescein and a sugar | |
| CN1087628C (en) | Developer for supersonic diagnosis of oviduct and its use | |
| Boll et al. | Studies on the juxtaglomerular apparatus: IV. Freeze-fracturing of membrane surfaces | |
| Maruyama et al. | Grey-scale contrast enhancement in rabbit liver with DMP115 at different acoustic power levels | |
| Hua et al. | Effects of diagnostic contrast-enhanced ultrasound on permeability of placental barrier: a primary study | |
| Gaton et al. | The effect of estrogen and gestagen on the mucus production of human endocervical cells: a histochemical study | |
| Oerke et al. | Detection of pregnancy and monitoring patterns of uterine and fetal growth in the marmoset monkey (Callithrix jacchus) by real‐time ultrasonography | |
| Haust et al. | Heparitin sulfate mucopolysaccharidosis (Sanfilippo disease): A case study with ultrastructural, biochemical, and radiological findings | |
| Metzger et al. | Transplacental arteriovenous gradients for glucose, insulin, glucagon and placental lactogen during normoglycaemia in human pregnancy at term | |
| Santolaya-Forgas et al. | Extracoelomic fluid osmometry and electrolyte composition during early gestation in the baboon | |
| EP1053026B1 (en) | Contrast medium based on polyoxethylene-660-12-hydroxystearate and anionic phospholipids | |
| CN108514644B (en) | Short T2 effect rectal/vaginal cavity internal magnetic resonance imaging contrast agent and preparation method thereof | |
| Amano et al. | Magnetic resonance imaging of bladder hemangioma | |
| CN107115534A (en) | A kind of intestines and stomach diagnostic imaging imaging assistant and preparation method thereof | |
| WO2022096089A1 (en) | Contact medium | |
| Yousry et al. | Exploring of ovulation time in bitches by utilizing cytological surveyand doppler ultrasonography | |
| Maxmudovich | PATHOHISTOLOGICAL STUDY OF THE PANCREAS OF PREGNANT RATS WITH EXPERIMENTAL DIABETES | |
| Jellins et al. | Ultrasonic imaging of the scrotum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |